J. Korzenik

A. Coates, J. Korzenik, E. Barnes, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Environmental Triggers for IBD

J. Korzenik, A. O'Toole, 2014, Current Gastroenterology Reports.

Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohn's Disease? A Decision Analysis

A. Ananthakrishnan, J. Korzenik, C. Hur, 2013, Inflammatory bowel diseases.

Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.

J. Korzenik, 2004, Gastroenterology clinics of North America.

Suicidal Behavior Among Hospitalized Adults With Inflammatory Bowel Disease: A United States Nationwide Analysis.

A. Nadkarni, J. Korzenik, E. Barnes, 2017, Inflammatory bowel diseases.

Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database

Allison R. Schulman, E. McCarthy, J. Korzenik, 2016, Inflammatory bowel diseases.

Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis

A. Ananthakrishnan, J. Korzenik, C. Hur, 2011, The American Journal of Gastroenterology.

Iatrogenic Trichuris suis infection in a patient with Crohn disease.

K. Badizadegan, P. Auluck, J. Korzenik, 2006, Archives of pathology & laboratory medicine.

Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease

Amit P. Desai, A. Ananthakrishnan, J. Korzenik, 2013, Inflammatory bowel diseases.

Is Crohn’s disease due to defective immunity?

J. Korzenik, 2006, Gut.

A probabilistic pathway score (PROPS) for classification with applications to inflammatory bowel disease

Russ B. Altman, Lichy Han, Mateusz Maciejewski, 2017, Bioinform..

Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis

H. Weiner, A. Ananthakrishnan, S. Snapper, 2019, Crohn's & colitis 360.

Novel Nonbiologic Therapies for Ulcerative Colitis

J. Korzenik, P. Juillerat, 2014 .

A case-control study of maternal knowledge of malnutrition and health-care-seeking attitudes in rural South India.

J. Korzenik, J. Jekel, S. Bhattacharji, 1997, The Yale journal of biology and medicine.

Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease

J. Korzenik, S. Tannenbaum, G. Wogan, 2013, Proceedings of the National Academy of Sciences.

An open‐labelled study of granulocyte colony‐stimulating factor in the treatment of active Crohn's disease

J. Korzenik, B. Dieckgraefe, Joshua R. Korzenik, 2005, Alimentary pharmacology & therapeutics.

Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor

J. Korzenik, B. Dieckgraefe, 2002, The Lancet.

An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease

Robert Langer, Giovanni Traverso, Matthew J. Hamilton, 2015, Science Translational Medicine.

Heparin‐Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine

J. Lennerz, J. Korzenik, G. Traverso, 2020, Advanced healthcare materials.

Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators.

J. Korzenik, 2005, Journal of clinical gastroenterology.

Metabolic analyses reveal dysregulated NAD+ metabolism and altered mitochondrial state in ulcerative colitis

J. Korzenik, M. Haigis, Sarah A Tucker, 2022, PloS one.

The Risk of Developing Crohn's Disease After an Appendectomy: A Meta-Analysis

G. Kaplan, J. Korzenik, B. Sands, 2008, The American Journal of Gastroenterology.

Sexual Dysfunction in Men With Inflammatory Bowel Disease: A New IBD-Specific Scale.

Linda G. Marc, J. Korzenik, M. Testa, 2018, Inflammatory bowel diseases.

Marijuana Use Patterns Among Patients with Inflammatory Bowel Disease

J. Korzenik, A. Courtwright, M. Lucci, 2013, Inflammatory bowel diseases.

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease

J. Korzenik, B. Sands, C. Bader, 2011, Gut.

Fatal outcome after embolotherapy for hepatic arteriovenous malformations of the liver in two patients with hereditary hemorrhagic telangiectasia.

J. Korzenik, R. White, J. Pollack, 2000, Journal of vascular and interventional radiology : JVIR.

Psoriasis associated with anti‐tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature

J. Korzenik, A. Cheifetz, D. Kroshinsky, 2011, Alimentary pharmacology & therapeutics.

Complementary and Integrative Gastroenterology.

J. Langhorst, J. Korzenik, A. Koch, 2017, The Medical clinics of North America.

Crohn's Cartography: Mapping Disease Patterns and Trajectories Using the Lémann Index-Are We Finding Our Way?

J. Korzenik, Renée M. Marchioni Beery, 2016, Journal of clinical gastroenterology.

The Role of Fiber in Diverticular Disease

J. Korzenik, Jessica E. Ravikoff, 2011 .

Case closed? Diverticulitis: epidemiology and fiber.

J. Korzenik, 2006, Journal of clinical gastroenterology.

Growth Factors as Treatment Options for Intestinal Inflammation

J. Korzenik, S. Anant, B. Dieckgraefe, 2006, Annals of the New York Academy of Sciences.

Natural History of Perianal Crohn's Disease After Fecal Diversion

A. Ananthakrishnan, J. Korzenik, J. Sauk, 2014, Inflammatory bowel diseases.

Characterization of patients with infliximab‐induced lupus erythematosus and outcomes after retreatment with a second anti‐TNF agent

J. Korzenik, B. Sands, V. Yajnik, 2011, Inflammatory bowel diseases.

Transition of Adolescents With Inflammatory Bowel Disease From Pediatric to Adult Care: A Survey of Adult Gastroenterologists

J. Korzenik, B. Sands, C. Valim, 2009, Journal of pediatric gastroenterology and nutrition.

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort

A. Ananthakrishnan, J. Korzenik, J. Allegretti, 2015, Inflammatory bowel diseases.

The changing epidemiology of inflammatory bowel disease: identifying new high-risk populations.

J. Korzenik, P. D. de Silva, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond: A Multicenter International Cohort

B. Burnand, A. Macpherson, H. Sokol, 2015, Inflammatory bowel diseases.

The risk of developing Crohn’s disease after an appendectomy: a population-based cohort study in Sweden and Denmark

B. V. Pedersen, G. Kaplan, J. Korzenik, 2007, Gut.

South Asian Patients With Inflammatory Bowel Disease in the United States Demonstrate More Fistulizing and Perianal Crohn Phenotype.

J. Korzenik, P. D. de Silva, Sushrut Jangi, 2020, Inflammatory bowel diseases.

Infliximab vs. Adalimumab for Crohn's disease: authors' reply

G. Kaplan, J. Korzenik, B. Sands, 2008 .

Mo1668 Mucosal Healing is a Cost-Effective Endpoint With Biologic Therapy in Crohns Disease - Results From a Decision Analysis

A. Ananthakrishnan, J. Korzenik, C. Hur, 2012 .

Risks and benefits of infliximab for the treatment of Crohn's disease.

G. Gazelle, J. Korzenik, B. Sands, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Challenges in IBD Research: Environmental Triggers.

Manolis Kellis, R. Judson, J. Krischer, 2019, Inflammatory bowel diseases.

Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery

J. Korzenik, E. Barnes, E. Collins, 2016, Digestive Diseases and Sciences.

Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab

A. Ananthakrishnan, J. Korzenik, E. Barnes, 2017, Digestive Diseases and Sciences.

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.

J. Korzenik, J. Leighton, D. Ramsey, 2010, Gastroenterology.

Diverticulitis: new frontiers for an old country: risk factors and pathogenesis.

J. Korzenik, 2008, Journal of clinical gastroenterology.

Identification of environmental factors that promote intestinal inflammation

A. Mildner, S. Snapper, J. Korzenik, 2022, Nature.

Caution with use of hepatic embolization in the treatment of hereditary hemorrhagic telangiectasia.

J. Korzenik, R. White, J. Whiting, 1999, Radiology.

CLINICAL—ALIMENTARY TRACT Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis

J. Korzenik, J. Leighton, D. Ramsey, 2010 .

Association of glycogen storage disease 1b and Crohn disease: results of a North American survey

J. Korzenik, B. Dieckgraefe, A. Husain, 2007, European Journal of Pediatrics.

Nutritional issues and therapy in inflammatory bowel disease.

J. Korzenik, A. Husain, 1998, Seminars in gastrointestinal disease.

Low-dose IL-2 for the Treatment of Moderate to Severe Ulcerative Colitis.

S. Snapper, A. Bousvaros, J. Korzenik, 2021, Gastroenterology.

Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease

B. Nørgård, J. Korzenik, J. Kjeldsen, 2019, Alimentary pharmacology & therapeutics.

Is Crohn's Disease an Immunodeficiency?

J. Korzenik, B. Dieckgraefe, 2000, Digestive Diseases and Sciences.

Gastrointestinal Vascular Malformations and Neoplasms: Arterial, Venous, Arteriovenous, and Capillary

J. Korzenik, A. Travis, 2015 .

Inflammatory bowel disease: a focus on the involvement of dietary fats

J. Korzenik, P. S. A. Silva, P. S. D. Silva, 2014 .

Probiotics for recurrent Clostridium difficile disease.

J. Korzenik, S. Lawrence, L. Mundy, 2005, Journal of medical microbiology.

Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases.

J. Langhorst, G. Dobos, J. Korzenik, 2015, Journal of Crohn's & colitis.

Crohn's disease: innate immunodeficiency?

J. Korzenik, J. Yamamoto-Furusho, Jesus-K Yamamoto-Furusho, 2006, World journal of gastroenterology.

A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis.

W. Willett, A. Ananthakrishnan, C. Fuchs, 2013, Gastroenterology.

Infliximab maintenance therapy for fistulizing Crohn's disease.

P. Rutgeerts, M. Kamm, C. Bernstein, 2004, The New England journal of medicine.

Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn’s Disease: Results of a Decision Analysis

A. Ananthakrishnan, J. Korzenik, C. Hur, 2012, Digestive Diseases and Sciences.

Non-Invasive Mapping of the Gastrointestinal Microbiota Identifies Children with Inflammatory Bowel Disease

Eric J. Alm, David B. Schauer, Ramnik J. Xavier, 2012, PloS one.

Sargramostim for active Crohn's disease.

J. Korzenik, B. Dieckgraefe, J. Valentine, 2005, The New England journal of medicine.

Association of glycogen storage disease 1b and Crohn disease: results of a North American survey

J. Korzenik, B. Dieckgraefe, A. Husain, 2002, European Journal of Pediatrics.

Dysregulation of reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes

J. Korzenik, S. Anant, B. Dieckgraefe, 2006, Cancer biology & therapy.

Perioperative Treatment with Infliximab in Patients with Crohn’s Disease and Ulcerative Colitis is Not Associated with an Increased Rate of Postoperative Complications

J. Korzenik, B. Sands, R. Hodin, 2008, Journal of Gastrointestinal Surgery.

Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis.

G. Kaplan, E. McCarthy, J. Korzenik, 2008, Gastroenterology.

The Practical Pros and Cons of Complementary and Alternative Medicine in Practice: Integrating Complementary and Alternative Medicine into Clinical Care.

J. Korzenik, R. Winter, 2017, Gastroenterology clinics of North America.

Mucosal Gene Expression in Pediatric and Adult Patients With Ulcerative Colitis Permits Modeling of Ideal Biopsy Collection Strategy for Transcriptomic Analysis.

S. Snapper, A. Bousvaros, J. Korzenik, 2018, Inflammatory bowel diseases.

Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial.

J. Korzenik, J. Marchesi, Sonia C. Timberlake, 2019, The American journal of gastroenterology.

Fecal Microbiota Transplantation in Patients with Primary Sclerosing Cholangitis: A Pilot Clinical Trial. Authors:

J. Korzenik, J. Marchesi, Sonia C. Timberlake, 2018 .

Liver disease in patients with hereditary hemorrhagic telangiectasia.

D. Jain, J. Korzenik, R. White, 2000, The New England journal of medicine.

Hereditary hemorrhagic telangiectasia and other intestinal vascular anomalies.

J. Korzenik, 1996, The Gastroenterologist.

Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses’ Health Study cohorts

D. Spiegelman, A. Ananthakrishnan, C. Fuchs, 2013, BMJ.

Blood-based Biomarkers Used to Predict Disease Activity in Crohn's Disease and Ulcerative Colitis

J. Korzenik, R. Odze, C. Liew, 2015, Inflammatory bowel diseases.

Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database

Christopher F. Martin, Seth D. Crockett, J. Korzenik, 2017, Inflammatory bowel diseases.

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association

G. Kaplan, P. Villeneuve, J. Korzenik, 2010, The American Journal of Gastroenterology.

International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia

A. Guttmacher, D. Ross, J. Piccirillo, 2009, Journal of Medical Genetics.

Functionally defective germline variants of sialic acid acetylesterase in autoimmunity

Annette Lee, P. Gregersen, T. Gillis, 2010, Nature.

Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy.

J. Korzenik, T. Klaenhammer, C. Kitts, 2009, Journal of medical microbiology.

Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease

T. Vatanen, D. Gevers, R. Xavier, 2016, Inflammatory bowel diseases.

Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease?

J. Korzenik, B. Sands, V. Ho, 2011, Surgery.

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost‐effectiveness analysis

G. Kaplan, J. Korzenik, B. Sands, 2007, Alimentary pharmacology & therapeutics.

Massive lower gastrointestinal hemorrhage in Crohn’s disease

J. Korzenik, 2000, Current treatment options in gastroenterology.

Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis

D. Gevers, D. Ward, J. Korzenik, 2011, Inflammatory bowel diseases.

Inflammatory bowel disease and environmental influences.

J. Korzenik, A. Krishnan, 2002, Gastroenterology clinics of North America.

Once Daily Dosing of Delayed-Release Oral Mesalamine (400 mg Tablet) is as Effective as Twice Daily Dosing for Maintenance of Remission of Ulcerative Colitis: Results of the QDIEM Study: 1185

J. Korzenik, J. Leighton, D. Ramsey, 2009 .

Creation of a Case-Finding Definition for Identifying Patients with Acute Pouchitis in Administrative Claims Data.

R. Sandler, J. Korzenik, J. Galanko, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Dietary behaviors in newly diagnosed youth with inflammatory bowel disease

Samir A. Shah, N. LeLeiko, J. Korzenik, 2017 .

SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease.

M. Daly, R. Xavier, A. Ananthakrishnan, 2014, Journal of Crohn's & colitis.

SMAD 3 gene variant is a risk factor for recurrent surgery in patients with Crohn ' s disease

R. Xavier, J. Korzenik, B. Sands, 2014 .

Efficacy of a Digital Personalized Elimination Diet for the Self-Management of Irritable Bowel Syndrome and Comorbid Irritable Bowel Syndrome and Inflammatory Bowel Disease

J. Korzenik, K. Wolin, Jordan Brown, 2022, Clinical and translational gastroenterology.

The Burden of Hospital Readmissions among Pediatric Patients with Inflammatory Bowel Disease

Christopher F. Martin, J. Korzenik, S. Crockett, 2017, The Journal of pediatrics.

Barriers to enrollment in inflammatory bowel disease randomized controlled trials: An investigation of patient perspectives

J. Korzenik, Joshua R Korzenik, Jessica E Ravikoff, 2012, Inflammatory bowel diseases.

Impact of Coexistent Celiac Disease on Phenotype and Natural History of Inflammatory Bowel Diseases

A. Ananthakrishnan, J. Korzenik, J. Sauk, 2013, The American Journal of Gastroenterology.

Long‐term outcome of a third anti‐TNF monoclonal antibody after the failure of two prior anti‐TNFs in inflammatory bowel disease

A. Ananthakrishnan, J. Korzenik, J. Sauk, 2012, Alimentary pharmacology & therapeutics.

Infectious Complications of Biologics

J. Korzenik, R. M. Beery, 2018 .

Flare factor: are there any triggering factors associated with onset of clinical symptoms or disease relapse?

J. Korzenik, 2008, Inflammatory bowel diseases.

A Prospective Study of Vitamin D Status and Risk of Incident Crohn's Disease and Ulcerative Colitis

E. Giovannucci, A. Ananthakrishnan, C. Fuchs, 2011 .

863 Higher Dietary Fiber Intake is Associated With Lower Risk of Crohn's Disease but Not Ulcerative Colitis - a Prospective Study

A. Ananthakrishnan, C. Fuchs, J. Korzenik, 2012 .

Polypoid vascular malformations of the small intestine.

M. Krinsky, J. Korzenik, M. Robert, 1998, Gastrointestinal endoscopy.

IBD: A Vascular Disorder? The Case for Heparin Therapy

J. Korzenik, 1997, Inflammatory bowel diseases.

Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial

M. Dubinsky, M. Regueiro, Todd A MacKenzie, 2022, Alimentary pharmacology & therapeutics.

Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease.

J. Korzenik, B. Dieckgraefe, 2000, Digestive diseases and sciences.

Impaired Innate Immune Function Associated with Fecal Supernatant from Crohn's Disease Patients: Insights into Potential Pathogenic Role of the Microbiome

J. Korzenik, C. Clish, D. Nguyen, 2014, Inflammatory bowel diseases.

Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated.

J. Korzenik, J. Allegretti, J. Marcus, 2021, Inflammatory bowel diseases.

Legalization of Medicinal Marijuana Has Minimal Impact on Use Patterns in Patients With Inflammatory Bowel Disease.

J. Korzenik, J. Allegretti, S. Friedman, 2018, Inflammatory bowel diseases.

Nutrition and dietary behaviors in pediatric Inflammatory Bowel Disease: P-64.

Samir A. Shah, N. LeLeiko, J. Korzenik, 2011 .

Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA

J. Korzenik, M. Lucci, A. O'Toole, 2016, Digestive Diseases and Sciences.

Transjugular intrahepatic portosystemic shunts in patients with hereditary hemorrhagic telangiectasia: failure to palliate gastrointestinal bleeding.

J. Korzenik, R. White, R. Demasi, 1998, Journal of vascular and interventional radiology : JVIR.

Colorectal cancer in Crohn’s colitis is comparable to sporadic colorectal cancer

Julie M. Batten, D. Park, A. Iafrate, 2016, International Journal of Colorectal Disease.

Development of a Sexual Dysfunction Scale for Women With Inflammatory Bowel Disease.

Linda G. Marc, A. Ananthakrishnan, J. Korzenik, 2018, Inflammatory bowel diseases.

Tu1993 Sexual Dysfunction in Women With Inflammatory Bowel Disease: A New IBD-Specific Scale

A. Ananthakrishnan, J. Korzenik, E. Collins, 2015 .

Mo1648 Irregular Bowel Movements Following Fecal Microbiota Transplantation (FMT) Are Associated With Pre-Existing Irritable Bowel Syndrome but Not FMT-Related Factors

J. Korzenik, Z. Kassam, J. Allegretti, 2016 .

The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD).

Elizabeth A. Scoville, Katerina O. Wells, R. Duerr, 2021, Inflammatory bowel diseases.

The Role of Diet-Fiber

J. Korzenik, Jessica E. Ravikoff, 2011 .

A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease.

B. Coull, S. Krawetz, N. Skakkebaek, 2016, Environment international.

Efficacy and Safety of Natalizumab in Crohn’s Disease Patients Treated at 6 Boston Academic Hospitals

J. Korzenik, S. Fowler, A. Cheifetz, 2013, Inflammatory bowel diseases.

Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease

J. Korzenik, E. Collins, J. Allegretti, 2015, Inflammatory bowel diseases.

Tu1266 Response to the Specific Carbohydrate Diet Amongst Individuals With Inflammatory Bowel Disease - A Survey of 122 Patients

J. Korzenik, P. S. A. Silva, W. Cole, 2015 .

Genomic and Clinical Effects Associated with a Relaxation Response Mind-Body Intervention in Patients with Irritable Bowel Syndrome and Inflammatory Bowel Disease

Sowmya R. Rao, G. Fricchione, M. Bhasin, 2015, PloS one.

Tu1361 Intestinal Microbiome Restoration for Recurrent Clostridium difficile Infection in Patients With Concurrent Inflammatory Bowel Disease

J. Korzenik, J. Allegretti, M. Hamilton, 2015 .

Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection.

J. Korzenik, J. Allegretti, M. Hamilton, 2014, Journal of visualized experiments : JoVE.

A crossover–crossback prospective study of dibutyl‐phthalate exposure from mesalamine medications and serum reproductive hormones in men

B. Coull, S. Krawetz, N. Skakkebaek, 2018, Environmental research.

796 Unrecognized Psychiatric Disease in Patients with Inflammatory Bowel Disease (IBD): Patients With Worse IBD Specific Patient Reported Outcome Measures Demonstrate Increased Anxiety and Depression Scores Even Without a Psychiatric History

A. Nadkarni, J. Korzenik, E. Barnes, 2016 .

Editorial: anti‐TNF therapy—a double‐edged sword? Authors' reply

B. Nørgård, J. Korzenik, J. Kjeldsen, 2019, Alimentary pharmacology & therapeutics.

Mo1754 Early Life Environment Interacts With Genetic Risk in Inflammatory Bowel Diseases

M. Daly, R. Xavier, A. Ananthakrishnan, 2015 .

Tu1270 Hygiene Factors in India and the US in Early Childhood Influence the Subsequent Development of Crohn's Disease but Not Ulcerative Colitis: A Large Case Controlled Study in Two Countries

Samir A. Shah, N. LeLeiko, J. Korzenik, 2012 .

Tu1288 Different Environmental Influences are Associated With the Development of IBD in India Compared to the US: A Case Controlled Study

Samir A. Shah, N. LeLeiko, J. Korzenik, 2012 .

S1195 Childhood Hygiene and IBD: A Case Control Study From India

J. Korzenik, B. Ramakrishna, M. Sahu, 2010 .

Heparin: An emerging, counterintuitive therapy for inflammatory bowel disease

J. Korzenik, 2000 .

Case records of the Massachusetts General Hospital. Case 33-2005. A 43-year-old man with lower gastrointestinal bleeding.

S. Digumarthy, K. Badizadegan, J. Korzenik, 2005, The New England journal of medicine.

Association of urinary phenolic compounds, inflammatory bowel disease and chronic diarrheal symptoms: Evidence from the National Health and Nutrition Examination Survey.

J. Korzenik, Xuan Yang, A. Caban-Martinez, 2017, Environmental pollution.

Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease

E. F. Cook, S. Schneeweiss, A. Ananthakrishnan, 2012, Alimentary pharmacology & therapeutics.

Dibutyl-phthalate exposure from mesalamine medications and serum thyroid hormones in men.

B. Coull, S. Krawetz, N. Skakkebæk, 2019, International journal of hygiene and environmental health.

Gut flora in health and disease

J. Korzenik, B. Dieckgraefe, 2003 .

Treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid.

J. Korzenik, R. White, M. Topazian, 1994, The New England journal of medicine.

Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.

J. Korzenik, D. Podolsky, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Psoriasis Associated With Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

J. Korzenik, A. Cheifetz, D. Kroshinsky, 2011 .

Validation of the Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F) in patients with inflammatory bowel disease

J. Korzenik, B. Sands, A. Tinsley, 2011, Alimentary pharmacology & therapeutics.

968 Infliximab Use in Patients with Inflammatory Bowel Disease and the Risk of Serious Bacterial Infections

S. Schneeweiss, D. Solomon, J. Korzenik, 2008 .

Immune stimulation in Crohn's disease: Safety and efficacy of rhuGM-CSF for the treatment of active Crohn's disease

J. Korzenik, Brian K. Dieckgraete, 2001 .

Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections

S. Schneeweiss, D. Solomon, J. Korzenik, 2009, Alimentary pharmacology & therapeutics.

Bile Acid Profiles are Not Altered by Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis: Category Award (Liver): Presidential Poster Award

J. Korzenik, J. Marchesi, Sonia C. Timberlake, 2018, American Journal of Gastroenterology.

Immunostimulation in Crohn's disease: Results of a pilot study of G-CSF (r-metHuG-CSF) in mucosal and fistulizing Crohn's disease

J. Korzenik, B. Dieckgraefe, 2000 .

Controlled Delivery of Bile Acids to the Colon

R. Langer, J. Korzenik, G. Traverso, 2020, Clinical and translational gastroenterology.

Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease

T. Vatanen, D. Gevers, R. Xavier, 2016, Inflammatory bowel diseases.

Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease

J. Korzenik, E. Collins, J. Allegretti, 2015, Inflammatory bowel diseases.

An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease

J. Karp, R. Langer, J. Korzenik, 2015, Science Translational Medicine.

Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators.

J. Korzenik, 2005, Journal of clinical gastroenterology.

Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles

Sean M. Kearney, G. Gerber, L. Bry, 2016, Alimentary pharmacology & therapeutics.

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.

J. Korzenik, J. Leighton, D. Ramsey, 2010, Gastroenterology.

Psoriasis associated with anti‐tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature

J. Korzenik, A. Cheifetz, D. Kroshinsky, 2011, Alimentary pharmacology & therapeutics.

Dysfunction of the intestinal microbiome in inflammatory bowel

Samir A. Shah, K. Devaney, D. Ward, 2013 .

ALIMENTARY TRACT: INTESTINE

J. Korzenik, 2005 .

Natural History of Perianal Crohn's Disease After Fecal Diversion

A. Ananthakrishnan, J. Korzenik, J. Sauk, 2014, Inflammatory bowel diseases.

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort

A. Ananthakrishnan, J. Korzenik, J. Allegretti, 2015, Inflammatory bowel diseases.

Don't Worry, Be Happy: Psychological Interventions in Inflammatory Bowel Disease.

J. Korzenik, 2019, Gastroenterology.